A grant from the National Institutes of Health’s National Institute on Aging will support a phase 3 study of Alzheon’s lead Alzheimer’s disease program in a genetically defined patient population. (NIH) Read the full article here
NIA Backs Alzheon’s Phase III Alzheimer’s Trial with $47 Million Grant
alzheon2020-08-21T15:07:35-04:00Framingham, Massachusetts-based Alzheon was awarded a $47 million grant over five years from the U.S. National Institute on Aging (NIA), part of the National Institutes of Health. The grant is to assist with a Phase III clinical trial of ALZ-801. Read the full article here